Sanofi sues Eli Lilly over challenge to top diabetes drug Lantus (Reuters). Reference links: Sanofi files suit in the US to defend its patent rights (Sanofi press release, PDF).

Sanofi’s Dupixent and new drugs drive growth, despite near-term pressures. See why SFY stock’s product pipeline makes it a ...

Sanofi's rivals in the insulin field are nipping at its heels – Lantus sales dipped 5 per cent in the first half of 2015, and analysts don't expect Toujeo to make up for its decline.

The French firm announced a $35 (£28) per month price cap on Lantus for those with private insurance. Sanofi's changes follow in the footsteps of other drugmakers, Eli Lilly and Novo Nordisk.

GoodRx said in a statement that it is working with Sanofi to offer U.S. insulin patients a coupon for to a 30-day supply of Lantus, an insulin glargine injection and Sanofi's most widely ...

As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.S. and China, Sanofi has picked up China rights to the cardiovascular candidate. The rights will be transferred from ...

It sells products through independent distributors primarily in India.Sanofi Indias products viz. Lantus, Combiflam, Amaryl and Allegra feature in the top 100 pharmaceutical brands in India.

New Delhi, Mar 11 () Biotechnology major Biocon on Wednesday said a US court has invalidated a Sanofi patent on the insulin glargine device, thus removing a legal hurdle to commercialising Semglee ...